Addition of serum sodium into the MELD score predicts waiting list mortality better than MELD alone

In this study, we investigated the prognostic value of serum sodium and hyponatremia (≤130 mEq/L) in 262 cirrhotic patients consecutively listed, 19 of which died (7%), 175 survived (67%), and 68 underwent liver transplantation (26%) during 3 months of follow‐up. Hyponatremia was present in 63% of patients who died, compared to 13% of those who survived (P < .001), whereas the proportion with elevated creatinine (≥1.4 mg/dL) was low and similar in both groups (10.5 vs. 3%). Prevalence of hyponatremia was higher than that of elevated serum creatinine across all model for end‐stage liver disease (MELD) categories. Using logistic regression, hyponatremia and serum sodium were significant predictors of mortality with concordance statistics (c‐statistics) .753 for hyponatremia, .784 for sodium, .894 for MELD, .905 for MELD plus hyponatremia (P = .006 vs. MELD alone), and .908 for MELD plus serum sodium (P = .026 vs. MELD alone). Risk of death across all MELD scores was higher for patients with hyponatremia than without hyponatremia. Cox regression considering data within 6 months of follow‐up yielded qualitatively similar results, with hyponatremia being a significant predictor of greater mortality risk with an odds ratio of 2.65 (P = .015). Each increase of 1 mEq/L of serum sodium level was associated with a decreased odds ratio of .95 (P = .048). Our results indicate that hyponatremia appears to be an earlier and more sensitive marker than serum creatinine to detect renal impairment and / or circulatory dysfunction in patients with advanced cirrhosis. In conclusion, addition of serum sodium to MELD identified a subgroup of patients with poor outcome in a more efficient way than MELD alone and significantly increased the efficacy of the score to predict waitlist mortality. (Liver Transpl 2005;11:336–343.)

[1]  J. Hanley,et al.  The meaning and use of the area under a receiver operating characteristic (ROC) curve. , 1982, Radiology.

[2]  J. Llach,et al.  Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites. , 1988, Gastroenterology.

[3]  C. Goodman United Network for Organ Sharing , 1988 .

[4]  J. Llach,et al.  Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. , 1988, Gastroenterology.

[5]  W. Jiménez,et al.  Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. , 1993, Gastroenterology.

[6]  J. Llovet,et al.  Renal impairment after spontaneous bacterial peritonitis in cirrhosis: Incidence, clinical course, predictive factors and prognosis , 1994, Hepatology.

[7]  W. Jiménez,et al.  Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. , 1996, Gastroenterology.

[8]  J. Schölmerich,et al.  Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis , 1996, Hepatology.

[9]  F. Harrell,et al.  Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors , 2005 .

[10]  W. Jiménez,et al.  Paracentesis-induced circulatory dysfunction: mechanism and effect on hepatic hemodynamics in cirrhosis. , 1997, Gastroenterology.

[11]  R. Sorelle United Network for Organ Sharing. , 1997, Circulation.

[12]  T. Berl,et al.  Hyponatremia in cirrhosis: From pathogenesis to treatment , 1998, Hepatology.

[13]  M. Andreu,et al.  Total paracentesis in cirrhotic patients with tense ascites and dilutional hyponatremia , 1999, American Journal of Gastroenterology.

[14]  M. Navasa,et al.  Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. , 1999, The New England journal of medicine.

[15]  Eter,et al.  A COMPARISON OF PARACENTESIS AND TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNTING IN PATIENTS WITH ASCITES , 2000 .

[16]  A. Maggi,et al.  Clinical relevance of hyponatraemia for the hospital outcome of cirrhotic patients. , 2000, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[17]  T M Therneau,et al.  A model to predict survival in patients with end‐stage liver disease , 2001, Hepatology.

[18]  R. Bataller,et al.  A prognostic model for predicting survival in cirrhosis with ascites. , 2001, Journal of hepatology.

[19]  P. Thuluvath,et al.  Pretransplant renal function predicts survival in patients undergoing orthotopic liver transplantation , 2002, Hepatology.

[20]  L. Martín-Herrera,et al.  Dilutional hyponatremia in patients with cirrhosis and ascites. , 2002, Archives of internal medicine.

[21]  D. Fish,et al.  Assessing renal function in cirrhotic patients: problems and pitfalls. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[22]  R. Wiesner,et al.  Model for end-stage liver disease (MELD) and allocation of donor livers. , 2003, Gastroenterology.

[23]  T. Sauerbruch,et al.  Prognostic Impact of Renal Impairment and Sodium Imbalance in Patients Undergoing Transjugular Intrahepatic Portosystemic Shunting for the Prevention of Variceal Rebleeding , 2003, Digestion.

[24]  P. Thuluvath,et al.  A vasopressin receptor antagonist (VPA‐985) improves serum sodium concentration in patients with hyponatremia: A multicenter, randomized, placebo‐controlled trial , 2003, Hepatology.

[25]  R. Moreau,et al.  The management of ascites in cirrhosis: Report on the consensus conference of the international Ascites club , 2003, Hepatology.

[26]  R. Wiesner,et al.  Improving liver allocation: MELD and PELD , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.